[go: up one dir, main page]

MX2017012068A - Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos. - Google Patents

Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos.

Info

Publication number
MX2017012068A
MX2017012068A MX2017012068A MX2017012068A MX2017012068A MX 2017012068 A MX2017012068 A MX 2017012068A MX 2017012068 A MX2017012068 A MX 2017012068A MX 2017012068 A MX2017012068 A MX 2017012068A MX 2017012068 A MX2017012068 A MX 2017012068A
Authority
MX
Mexico
Prior art keywords
new
agents
lif
malignities
anticonceptive
Prior art date
Application number
MX2017012068A
Other languages
English (en)
Other versions
MX385372B (es
Inventor
Nickisch Klaus
Santhamma Bindu
Nair Hareesh
Original Assignee
Evestra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evestra Inc filed Critical Evestra Inc
Publication of MX2017012068A publication Critical patent/MX2017012068A/es
Publication of MX385372B publication Critical patent/MX385372B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a nuevos compuestos anti-cáncer y métodos para usar tales compuestos, actuando a través de un mecanismo de acción por inhibición simultánea del factor inhibidor de leucemia (LIF) y MDM2. En una modalidad, un compuesto citotóxico tiene la estructura (I) o (II). En una modalidad, un método para tratar el cáncer en un sujeto comprende administrar a un sujeto un medicamento que comprende una cantidad efectiva de un compuesto citotóxico de molécula pequeña que inhibe el factor inhibidor de leucemia o receptor del factor inhibidor de leucemia.
MX2017012068A 2015-03-23 2016-03-22 Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos MX385372B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562136813P 2015-03-23 2015-03-23
PCT/US2016/023582 WO2016154203A1 (en) 2015-03-23 2016-03-22 Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents

Publications (2)

Publication Number Publication Date
MX2017012068A true MX2017012068A (es) 2018-06-28
MX385372B MX385372B (es) 2025-03-18

Family

ID=56975094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012068A MX385372B (es) 2015-03-23 2016-03-22 Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos

Country Status (6)

Country Link
US (2) US10053485B2 (es)
EP (1) EP3273983B1 (es)
AU (1) AU2016235298B2 (es)
CA (1) CA2981173C (es)
MX (1) MX385372B (es)
WO (1) WO2016154203A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014287049B2 (en) * 2013-07-11 2019-09-26 Evestra, Inc. Pro-drug forming compounds
MX391191B (es) 2014-11-17 2025-03-21 Context Biopharma Inc Composiciones de liberación extendida de onapristona y métodos.
MX385372B (es) * 2015-03-23 2025-03-18 Evestra Inc Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos
JP2018528944A (ja) * 2015-09-25 2018-10-04 コンテクスト バイオファーマ インコーポレイテッド オナプリストン中間体の製造方法
KR20180113988A (ko) 2015-12-15 2018-10-17 컨텍스트 바이오파마 인코포레이티드 비정질 오나프리스톤 조성물 및 그 제조방법
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
CA2045126A1 (en) 1989-01-10 1990-07-11 Nicholas M. Gough Leukaemia inhibitory factor from livestock species and use thereof to enhance implantation and development of embryonic cells
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1993023556A1 (en) 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
WO1995010298A1 (en) 1993-10-12 1995-04-20 Mary Lake Polan Method of contraception
US5573762A (en) 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
US5948822A (en) 1996-12-17 1999-09-07 Lidak Pharmaceuticals Treatment of hyperproliferative skin disorders with C18 to C26 alphatic alcohols
US6156729A (en) 1997-10-15 2000-12-05 California Institute Of Technology Leukemia inhibitory factor for use in modulating inflammation and pain
US8784763B2 (en) * 2009-03-13 2014-07-22 Honeywell International Inc. Methods and reactor designs for producing phosphorus pentafluoride
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US20130274215A1 (en) * 2010-04-08 2013-10-17 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
AU2014287049B2 (en) * 2013-07-11 2019-09-26 Evestra, Inc. Pro-drug forming compounds
TWI486172B (zh) 2013-11-08 2015-06-01 長庚大學 鼻咽癌治療的醫藥
MX385372B (es) * 2015-03-23 2025-03-18 Evestra Inc Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos

Also Published As

Publication number Publication date
US10738075B2 (en) 2020-08-11
US10053485B2 (en) 2018-08-21
AU2016235298B2 (en) 2021-03-11
US20160279145A1 (en) 2016-09-29
CA2981173A1 (en) 2016-09-29
EP3273983A4 (en) 2018-12-05
WO2016154203A1 (en) 2016-09-29
EP3273983B1 (en) 2021-05-05
AU2016235298A1 (en) 2017-10-19
US20190153018A1 (en) 2019-05-23
EP3273983A1 (en) 2018-01-31
CA2981173C (en) 2024-01-02
MX385372B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
MX2017012068A (es) Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
DOP2019000266A (es) Inhibidores de pd-1/pd-l1
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
CL2018001591A1 (es) Compuestos útiles como inhibidores de cinasa.-
DOP2019000201A (es) Compuestos inhibidores del vih
CL2019000844A1 (es) Compuesto de piridina.
CL2019000266A1 (es) Composición de cannabis.
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
CO2018004750A2 (es) Composiciones para inhibir la actividad arginasa
CR20150416A (es) Inhibidores de cdc7
PH12018501669A1 (en) Compositions containing tucaresol or its analogs
MX377384B (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
MX392014B (es) Composiciones y métodos para modular la expresión de angiotensinógeno.
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
MX2017013801A (es) Métodos para tratar el cáncer.
MX2013008376A (es) Composiciones y metodos para el tratamiento de cancer.
ECSP17029203A (es) Inhibidor de cinasa aurora a
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
MX390503B (es) Compuesto de pirimidina fusionada o sal del mismo.
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
CR20180495A (es) Deribados de indol sustituidos como inhibidores de replicación viral del dengue